This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
by Zacks Equity Research
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
by Zacks Equity Research
Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline
by Zacks Equity Research
Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.
Sarepta Signs Gene Therapy Agreement With Roche for $1.15B
by Zacks Equity Research
Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up
by Zacks Equity Research
Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Company News for Dec 4, 2019
by Zacks Equity Research
Companies In The News Are: UNH,PEP,CLF,AKS,BOLD.
Sarepta Stock Falls as FDA Denies Approval to Golodirsen
by Zacks Equity Research
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
by Zacks Equity Research
Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Audentes Therapeutics (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BOLD) Outperforming Other Medical Stocks This Year?
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season?
by Zacks Equity Research
Audentes Therapeutics (BOLD) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%
by Zacks Equity Research
Audentes Therapeutics, Inc. (BOLD) was a big mover last session, as the company saw its shares nearly 15% on the day amid huge volumes.
Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge
by Zacks Equity Research
Audentes Therapeutics (BOLD) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.